In the clinical practice, angiotensin converting enzyme (ACE) inhibition or angiotensin receptor blockade is still most common strategy against membranous nephropathy or, rather, more aggressive treatment using glucocorticoids and alkylating agents [5]. The gene discussed is ACE; the disease is membranous glomerulonephritis.